Amryt Pharma pleased with progress, announces new in-licence agreement

Rare and orphan disease-focussed biopharmaceutical company Amryt Pharma updated the market on its trading on Thursday, and announced that it has concluded terms for an exclusive in-licence agreement for a novel gene therapy platform, offering a “potentially exciting” treatment for patients with epidermolysis bullosa (EB).